A class of direct purchasers who allege that Pfizer used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have reached a $94 million settlement agreement with Pfizer.

Continue reading “Pfizer settles Celebrex antitrust class action for $94 million”